Stage II/III Colorectal Cancer Recurrence

Recruiting now

Conditions studied: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent

In brief

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

Key facts

Study ID

NCT06314958

Run by

City of Hope Medical Center

People needed

400

Starts

2023-03-15

Expected to finish

2028-06-18

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition).
• Received standard diagnostic, staging, and therapeutic procedures as per local guidelines
• Received stage-specific curative-intent resection followed by adjuvant chemotherapy.
• Confirmed cancer-free survivorship confirmed at the time of study inclusion.

You may not qualify if…

• Lack of written informed consent.
• Development of recurrence in the first 6 months following adjuvant chemotherapy completion.
• Hereditary colorectal cancer syndromes (identified through genetic testing)
• Inflammatory bowel diseases

Where it is running

• City of Hope Medical Center — Monrovia, California, United States (enrolling)
• Second Affiliated Hospital of Dalian Medical University — Dalian, China (enrolling)
• Barcelona University — Barcelona, Spain (enrolling)
• La Paz University Hospital — Madrid, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.